A novel approach to identify Duchenne muscular dystrophy patients for aminoglycoside antibiotics therapy

详细信息	查看全文 | 推荐本文 |

• 作者：Shigemi Kimura ; Kaori Ito ; Toshihiko Miyagi ; Takashi Hiranuma ; Kowasi Yoshioka ; Shirou Ozasa ; Makoto Matsukura ; Makoto Ikezawa ; Masafumi Matsuo ; Yasuhiro Takeshima and Teruhisa Miike
• 刊名：Brain and Development
• 出版年：2005
• 期刊代码：40_03877604
• 类别：med
• 出版时间：2005
• 卷：27
• 期：6
• 页码：400-405
• 文件大小：180 K

摘要

Aminoglycoside antibiotics have been found to suppress nonsense mutations located in the defective dystophin gene in mdx mice, suggesting a possible treatment for Duchenne muscular dystrophy (DMD). However, it is very difficult to find patients that are applicable for this therapy, because: (1) only 5-13%of DMD patients have nonsense mutations in the dystrophin gene, (2) it is challenging to find nonsense mutations in the gene because dystrophin cDNA is very long (14 kb), and (3) the efficiency of aminoglycoside-induced read-through is dependent on the kind of nonsense mutation. In order to develop a system for identifying candidates that qualify for aminoglycoside therapy, fibroblasts from nine DMD patients with nonsense mutation of dystrophin gene were isolated, induced to differentiate to myogenic lineage by AdMyoD, and exposed with gentamicin. The dystrophin expression in gentamicin-exposed myotubes was monitored by in vitro dystrophin staining and western blotting analysis. The results showed that gentamicin was able to induce dystrophin expression in the differentiated myotubes by the read-through of the nonsense mutation TGA in the gene; a read-through of the nonsense mutations TAA and TAG did not occur and consequently did not lead to dystrophin expression. Therefore, it is speculated that the aminoglycoside treatment is far more effective for DMD patients that have nonsense mutation TGA than for patients that have nonsense mutation TAA and TAG. In this study, we introduce an easy system to identify patients for this therapy and report for the first time, that dystrophin expression was detected in myotubes of DMD patients using gentamicin.